NASDAQ:INVO INVO Bioscience (INVO) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free INVO Stock Alerts $1.08 -0.02 (-1.82%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.08▼$1.1750-Day Range$0.85▼$1.2652-Week Range$0.50▼$13.52Volume14,363 shsAverage Volume20,667 shsMarket Capitalization$2.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get INVO Bioscience alerts: Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About INVO Bioscience Stock (NASDAQ:INVO)INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. INVO Bioscience, Inc. was founded in 2007 and is based in Sarasota, Florida.Read More INVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVO Stock News HeadlinesMarch 27, 2024 | americanbankingnews.comINVO Bioscience (NASDAQ:INVO) vs. Arch Therapeutics (OTCMKTS:ARTH) Head-To-Head ContrastMarch 27, 2024 | americanbankingnews.comINVO Bioscience (NASDAQ:INVO) Stock Price Down 8.8%March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 22, 2024 | benzinga.comINVO Bioscience Stock (NASDAQ:INVO), Short Interest ReportFebruary 4, 2024 | morningstar.comINVO Bioscience Inc INVOJanuary 23, 2024 | marketwatch.comINVO BioScience Shares Up 5% as NAYA Agrees to Buy Florida BiotechnologiesJanuary 23, 2024 | finance.yahoo.comNAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)January 23, 2024 | finance.yahoo.comNAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.January 17, 2024 | finance.yahoo.comINVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board DirectorsDecember 23, 2023 | finance.yahoo.comINVO Bioscience, Inc. (INVO) Stock Historical Prices & Data - Yahoo FinanceDecember 11, 2023 | finance.yahoo.comNAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood JournalDecember 6, 2023 | msn.comNAYA, ONK team up to evaluate potential cancer therapy combinationsDecember 6, 2023 | finance.yahoo.comNAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell TherapiesNovember 28, 2023 | finance.yahoo.comINVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementNovember 14, 2023 | benzinga.comWhy INVO Bioscience Shares Are Trading Higher By Over 31%; Here Are 20 Stocks Moving PremarketNovember 13, 2023 | finance.yahoo.comINVO Reports Record Third Quarter 2023 Financial ResultsNovember 13, 2023 | msn.comWhat's Going On With INVO BioScience Stock?November 13, 2023 | finance.yahoo.comBestGrowthStocks.Com Issues Comprehensive Analysis Regarding INVO Biosciences MergerNovember 10, 2023 | benzinga.comWhy Is Fertility Treatment-Focused Firm INVO Bioscience Stock Trading Over 100% Higher Today?November 10, 2023 | finance.yahoo.comNAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending MergerNovember 9, 2023 | finance.yahoo.comINVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase WarrantsOctober 30, 2023 | msn.comBHAT and INVO among pre-market losersOctober 27, 2023 | finance.yahoo.comFree Registration Is Now Open For Tribe Public's CEO and Q&A Presentation Webinar Event "Accelerating Biotech Value Creation" Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023October 24, 2023 | businesswire.comINVO BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of INVO Bioscience, Inc. - INVOOctober 24, 2023 | benzinga.comWhy INVO BioScience Stock Dropped Today, Trading Also Halted Several TimesOctober 24, 2023 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HES, ESMT, INVO, TGHSee More Headlines Receive INVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INVO Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/29/2024Next Earnings (Estimated)4/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:INVO CUSIPN/A CIK1417926 Webwww.invobioscience.com Phone(978) 878-9505FaxN/AEmployees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($12.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,890,000.00 Net Margins-459.42% Pretax MarginN/A Return on Equity-7,630.09% Return on Assets-88.87% Debt Debt-to-Equity Ratio2.94 Current Ratio0.37 Quick Ratio0.31 Sales & Book Value Annual Sales$820,000.00 Price / Sales3.25 Cash FlowN/A Price / Cash FlowN/A Book Value($1.61) per share Price / Book-0.67Miscellaneous Outstanding Shares2,470,000Free Float2,388,000Market Cap$2.67 million OptionableNo Data Beta1.45 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Steven M. Shum (Age 53)CEO & Director Comp: $260kMr. Andrea Goren (Age 57)Chief Financial Officer Comp: $215kMr. Michael Jos. Campbell (Age 66)COO & VP of Business Development Comp: $220kMr. Bojan Mitrovic Ph.D.Director of Sales USMr. Robert Joseph Bowdring Jr. (Age 66)Treasurer & Secretary Ms. Terah KrigsvoldControllerMore ExecutivesKey CompetitorsG Medical InnovationsNASDAQ:GMVDFNemaura MedicalNASDAQ:NMRDReShape LifesciencesNASDAQ:RSLSTenon MedicalNASDAQ:TNONMotus GINASDAQ:MOTSView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 54,058 shares on 3/11/2024Ownership: 2.189%Vanguard Group Inc.Bought 54,058 shares on 2/15/2024Ownership: 2.184%View All Institutional Transactions INVO Stock Analysis - Frequently Asked Questions How have INVO shares performed in 2024? INVO Bioscience's stock was trading at $1.35 at the beginning of 2024. Since then, INVO stock has decreased by 20.0% and is now trading at $1.08. View the best growth stocks for 2024 here. When is INVO Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 15th 2024. View our INVO earnings forecast. How were INVO Bioscience's earnings last quarter? INVO Bioscience, Inc. (NASDAQ:INVO) announced its earnings results on Monday, November, 15th. The company reported ($4.80) earnings per share for the quarter, missing the consensus estimate of ($4.00) by $0.80. The business earned $0.22 million during the quarter, compared to the consensus estimate of $0.25 million. INVO Bioscience had a negative trailing twelve-month return on equity of 7,630.09% and a negative net margin of 459.42%. During the same quarter in the previous year, the business posted ($7.20) earnings per share. When did INVO Bioscience's stock split? INVO Bioscience's stock reverse split before market open on Thursday, July 27th 2023. The 1-20 reverse split was announced on Thursday, July 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are INVO Bioscience's major shareholders? INVO Bioscience's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.19%), Vanguard Group Inc. (2.18%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrea Goren, Awm Investment Company, Inc, Matthew K Szot, Michael Jos Campbell and Steve Shum. View institutional ownership trends. How do I buy shares of INVO Bioscience? Shares of INVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INVO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.